ICML 2017 | Next steps for the use of ibrutinib and venetoclax for the treatment of lymphoma
Constantine Tam, MBBS, MD, FRACP, FRCPA from the University of Melbourne, Melbourne, Australia discusses the next steps for the use of ibrutinib, venetoclax and other agents for the treatment of lymphoma. Prof. Tam explains that we need to find the best combinations from the drugs that are already known to be active. We also need to learn how to sequence these drugs in order to get the best outcome. Further, we need to learn their weaknesses in order to develop second and third generations drugs that overcome these weaknesses.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.
Get great new content delivered to your inboxSign up